Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Abstract Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD) patients resulting in poor functional status and worse outcomes. Early recognition of PH in ILD is important for initiating therapy and considering lung transplantation. However, no standard exists rega...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Raj Parikh, Ippokratis Konstantinidis, David M. O'Sullivan, Harrison W. Farber
Natura:	Articolo
Lingua:	English
Pubblicazione:	Wiley 2022-10-01
Serie:	Pulmonary Circulation
Soggetti:	idiopathic pulmonary fibrosis interstitial lung disease prostacyclin pulmonary hypertension treprostinil
Accesso online:	https://doi.org/10.1002/pul2.12141

Documenti analoghi

The PH‐ILD Detection tool: External validation and use in patients with ILD
di: Raj Parikh, et al.
Pubblicazione: (2023-07-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
di: Julia McSweeney, et al.
Pubblicazione: (2023-04-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
di: Aparna C. Swaminathan, et al.
Pubblicazione: (2024-11-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
di: Jenna M. Faircloth, et al.
Pubblicazione: (2023-03-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
di: Jenna M. Faircloth, et al.
Pubblicazione: (2023-08-01)

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
di: Piotr Kędzierski, et al.
Pubblicazione: (2025-01-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
di: Abdullah A. Alqarni, et al.
Pubblicazione: (2023-08-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
di: Shelsey W. Johnson, et al.
Pubblicazione: (2022-07-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
di: Nicholas S. Hill, et al.
Pubblicazione: (2022-07-01)

Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future
di: Ahmad Arslan, et al.
Pubblicazione: (2024-01-01)

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis
di: Ning Zhao, et al.
Pubblicazione: (2022-11-01)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
di: Maria S. Nashatyreva, et al.
Pubblicazione: (2023-01-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
di: Garance Kopp, et al.
Pubblicazione: (2020-10-01)

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
di: Kellie Morland, et al.
Pubblicazione: (2021-10-01)

Interstitial Lung Abnormality in Asian Population
di: Gong Yong Jin
Pubblicazione: (2024-04-01)

The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases
di: Mingtao Liu, et al.
Pubblicazione: (2023-09-01)

CLINICAL PROFILE OF INTERSTITIAL LUNG DISEASES CASES
di: Gagiya Ashok K, et al.
Pubblicazione: (2012-03-01)

Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease
di: Alexandra Lawrence, et al.
Pubblicazione: (2024-09-01)

Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
di: Zachary A. Haynes, et al.
Pubblicazione: (2023-10-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
di: E. A. Rezukhina, et al.
Pubblicazione: (2021-09-01)

Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy
di: N. A. Kuzubova, et al.
Pubblicazione: (2020-11-01)

Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date
di: Cassady SJ, et al.
Pubblicazione: (2024-06-01)

Osteopontin as a Biomarker in Interstitial Lung Diseases
di: David Iturbe-Fernández, et al.
Pubblicazione: (2024-05-01)

Multidisciplinary discussion for diagnosis of interstitial lung disease in real life
di: Sabina Anna Guler, et al.
Pubblicazione: (2016-05-01)

Increased expiratory flows identify early interstitial lung disease
di: Sami Mohammed Alyami, et al.
Pubblicazione: (2023-01-01)

Role of Telomere Length in Survival of Patients with Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
di: Sofía Tesolato, et al.
Pubblicazione: (2023-12-01)

Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
di: Jonathan Keow, et al.
Pubblicazione: (2022-06-01)

Evaluation of progressive pulmonary fibrosis in non-idiopathic pulmonary fibrosis-interstitial lung diseases: a cross-sectional study
di: Özlem Erçen Diken, et al.
Pubblicazione: (2024-08-01)

Estimation of plasmic concentration of the brain natriuretic peptide in interstitial pulmonary diseases with pulmonary hypertension: clinical role
di: N A Mukhin, et al.
Pubblicazione: (2009-03-01)

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis
di: Lianghua Xiao, et al.
Pubblicazione: (2024-09-01)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
di: Justin M. Oldham, et al.
Pubblicazione: (2017-08-01)

Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis
di: Pierson Richard, et al.
Pubblicazione: (2002-02-01)

Abnormal platelet aggregation in pediatric pulmonary hypertension
di: Stephanie S. Handler, et al.
Pubblicazione: (2022-07-01)

Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis
di: Avignat S. Patel, et al.
Pubblicazione: (2023-02-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
di: Jia Liu, et al.
Pubblicazione: (2024-04-01)

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost
di: Ji Hoon Jang, et al.
Pubblicazione: (2024-08-01)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
di: Hardin EA, et al.
Pubblicazione: (2016-11-01)

An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J)
di: Kazuya Ichikado, et al.
Pubblicazione: (2023-06-01)

Noninvasive determinants of pulmonary hypertension in interstitial lung disease
di: Phillip Joseph, et al.
Pubblicazione: (2023-01-01)

Pulmonary Hypertension in the Course of Interstitial Lung Diseases—A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy
di: Aneta Kacprzak, et al.
Pubblicazione: (2023-07-01)